Fluorouracil and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fluorouracil (fluorouracil) and Ibrance (palbociclib). Common drug interactions include malignant neoplasm progression among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Fluorouracil and Ibrance. It is created by eHealthMe based on reports of 76 people who take the same drugs from the FDA, and is updated regularly.

What is Fluorouracil?

Fluorouracil has active ingredients of fluorouracil. It is often used in colon cancer metastatic. eHealthMe is studying from 97,087 Fluorouracil users. Check the latest studies of Fluorouracil.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

76 people who take Fluorouracil and Ibrance together, and have interactions are studied.

Fluorouracil and Ibrance drug interactions.

What are the common drug interactions of Fluorouracil and Ibrance, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Neoplasm progression (growth of tumour)
Platelet count decreased
Red blood cell count decreased
Metastasis (spreadable cancer to other organ from origin)
Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
Asthma
Chest discomfort
Haematochezia (passage of stools containing blood)
Haematocrit decreased

male:

Drug ineffective

What are the common drug interactions of Fluorouracil and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Arthralgia (joint pain)
Back pain
Cough
Decreased appetite
Fatigue (feeling of tiredness)
Malignant neoplasm progression (cancer tumour came back)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastases to liver (cancer spreads to liver)
Myalgia (muscle pain)
Nausea (feeling of having an urge to vomit)

50-59:

Disease progression
Drug ineffective
Blood pressure increased
Contusion (a type of hematoma of tissue in which capillaries)
Cough
Decreased appetite
Diarrhoea
Dry eye (lack of adequate tears)
Epistaxis (bleed from the nose)
Fatigue (feeling of tiredness)

60+:

Fatigue (feeling of tiredness)
White blood cell count decreased
Chest discomfort
Cough
Haematochezia (passage of stools containing blood)
Haematocrit decreased
Haemoglobin decreased
Red cell distribution width increased
Gastrointestinal toxicity (damage to digestive tract by any substance)
Neoplasm progression (growth of tumour)

What are the existing conditions these people have? *

Breast Cancer Metastatic: 38 people, 50.00%
Breast Cancer: 12 people, 15.79%
Metastasis (spreadable cancer to other organ from origin): 9 people, 11.84%
Breast Neoplasm (non cancerous tumour of breast): 5 people, 6.58%
Breast Cancer Female: 4 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Fluorouracil and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously